Performance analysis of Intellia Therapeutics (NTLA)
Annual Return
Over the past 3 years, NTLA has had an average annual return of -36.93%, underperforming the benchmark SPY, which returned +19.31% annual.
Over the past 5 years, NTLA has had an average annual return of -40.65%, underperforming the benchmark SPY, which returned +12.55% annual.
Over the past 10 years, NTLA has had an average annual return of -5.14%, underperforming the benchmark SPY, which returned +14.95% annual.
Since May 6, 2016, NTLA has had an average annual return of -6.67%, underperforming the benchmark SPY, which returned +15.25% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +21.46% | -22.90% | -61.76% | -12.61% | -70.49% | +117.36% | +270.82% | +7.48% | -28.99% | +46.61% | -40.68% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +46.26% | +4.79% | -6.96% | +5.15% | +4.38% | +20.25% | -35.46% | +21.46% | |||||
| 2025 | -11.49% | -2.23% | -29.54% | +24.77% | -22.55% | +36.51% | +24.10% | -2.45% | +52.08% | -26.93% | -28.76% | -0% | -22.90% |
| 2024 | -21.88% | +34.85% | -14.35% | -22.21% | -0.09% | +4.68% | +17.11% | -14.38% | -8.42% | -30.81% | +9.85% | -25.35% | -61.76% |
| 2023 | +21.64% | -5.35% | -7.22% | +1.29% | -1.29% | +9.44% | +3.80% | -11.46% | -15.63% | -20.78% | +18.28% | +2.90% | -12.61% |
| 2022 | -20.02% | +4.53% | -26.49% | -32.53% | -5.90% | +12.18% | +25.11% | -7.26% | -6.83% | -5.68% | -2.50% | -32.20% | -70.49% |
| 2021 | +15.11% | -3.45% | +32.74% | -4.34% | -2.38% | +116.05% | -12.39% | +13.17% | -16.43% | -0.87% | -13.51% | +2.81% | +117.36% |
| 2020 | -18.82% | +12.10% | -8.39% | +10.14% | +29.99% | +20.04% | -15.27% | +21.17% | -7.89% | +20.43% | +64.03% | +38.53% | +270.82% |
| 2019 | +3.59% | +7.71% | +12.16% | -9.96% | -9.74% | +17.93% | +10.57% | -21.60% | -5.92% | -6.49% | +38.82% | -15.35% | +7.48% |
| 2018 | +33.71% | +1.56% | -19.20% | -5.07% | +35.36% | +0.96% | -2.71% | +16.19% | -7.47% | -40.67% | +5.48% | -23.79% | -28.99% |
| 2017 | -1.45% | +10.54% | -1.33% | +3.40% | -21.34% | +39.61% | +5.25% | +24.88% | +18.16% | +25.23% | -27.63% | -14.65% | +46.61% |
Drawdown analysis of Intellia Therapeutics (NTLA)
The maximum drawdown for the NTLA was -96.45%, occurring on Apr 8, 2025. This drawdown has not yet recovered.
The current NTLA drawdown is -93.82%.
Since May 6, 2016 NTLA has experienced the following drawdowns:
- 50% or more: 3 times
- 40% or more: 5 times
- 30% or more: 6 times
- 20% or more: 7 times
- 10% or more: 10 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.45% | Sep 3, 2021 | 901 | Apr 8, 2025 | Ongoing | Ongoing | Ongoing |
| -72.99% | Mar 9, 2018 | 507 | Mar 16, 2020 | 178 | Nov 25, 2020 | 685 |
| -61.52% | May 31, 2016 | 251 | May 30, 2017 | 88 | Oct 3, 2017 | 339 |
| -44.32% | Jan 19, 2021 | 33 | Mar 8, 2021 | 34 | Apr 26, 2021 | 67 |
| -44.12% | Oct 31, 2017 | 31 | Dec 14, 2017 | 56 | Mar 8, 2018 | 87 |
| -30.07% | Apr 27, 2021 | 12 | May 13, 2021 | 21 | Jun 14, 2021 | 33 |
| -22.88% | Jul 1, 2021 | 17 | Jul 27, 2021 | 27 | Sep 2, 2021 | 44 |
| -14.81% | Oct 6, 2017 | 14 | Oct 26, 2017 | 3 | Oct 31, 2017 | 17 |
| -14.37% | Dec 22, 2020 | 6 | Dec 31, 2020 | 3 | Jan 6, 2021 | 9 |
| -14.36% | Jun 15, 2021 | 3 | Jun 18, 2021 | 5 | Jun 25, 2021 | 8 |
| -9.17% | May 10, 2016 | 3 | May 13, 2016 | 2 | May 17, 2016 | 5 |
| -7.12% | Jan 8, 2021 | 1 | Jan 11, 2021 | 3 | Jan 14, 2021 | 4 |
| -6.73% | Dec 10, 2020 | 2 | Dec 14, 2020 | 5 | Dec 21, 2020 | 7 |
| -4.15% | May 18, 2016 | 1 | May 19, 2016 | 2 | May 23, 2016 | 3 |
| -3.25% | Nov 27, 2020 | 2 | Dec 1, 2020 | 1 | Dec 2, 2020 | 3 |
| -2.62% | Oct 3, 2017 | 1 | Oct 4, 2017 | 2 | Oct 6, 2017 | 3 |
| -1.69% | Jan 14, 2021 | 1 | Jan 15, 2021 | 1 | Jan 19, 2021 | 2 |
| -0.49% | May 25, 2016 | 1 | May 26, 2016 | 1 | May 27, 2016 | 2 |